NCT06323837View on ClinicalTrials.gov

Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions
Stimulant Use Disorder
Interventions
DRUG

Mirtazapine

This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of mirtazapine (MZP) to increase methamphetamine (MA) abstinence among treatment-seeking medication for opioid use disorder (MOUD) adults.

DRUG

Placebo

Placebo to match.

Trial Locations (1)

99208

RECRUITING

Spokane Treatment Center, Spokane

All Listed Sponsors
lead

Washington State University

OTHER